地诺单抗主治什么？

(denosumab, also known as AMG-162, trade name Prolia) is a bone resorption inhibitor with a unique mechanism of action. It specifically targets the receptorctivator of NF-κBligand (RANKL), inhibits the activation and development of osteoclasts, reduces bone resorption, and increases bone density. On May 28, 2010, the European Commission approved this product for the treatment of bone loss related to hormone suppression in postmenopausal women with osteoporosis and prostate cancer patients. It can also be used in patients for whom other current treatments are ineffective or intolerable to reduce the risk of fractures. This product has been approved for the first time in 27 EU member states, as well as Norway, Iceland and Liechtenstein. In June of the same year, this product was approved by the FDA for marketing.

On May 27, 2019, Amgen China announced today that Angavir (English trade name:

Desosumab can only be given by subcutaneous injection, not by intravenous infusion, intramuscular infusion or intradermal injection. (1) Solid tumor bone metastasis: 120mg once every 4 weeks, injected subcutaneously in the upper arm, thigh or abdomen. (2) Giant cell tumor of bone: 120 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. (3) Administer calcium and vitamin D appropriately to prevent hypocalcemia. (4) Malignant hypercalcemia: 20 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen.

Common side effects include joint pain, headache, nausea, fatigue, back, hand and foot pain. The most common serious side effects are osteonecrosis of the jaw and osteomyelitis (inflammation or bone infection). Because denosumab has the potential to harm the fetus, women of childbearing potential must use highly effective contraception when using this drug.